Stock Research: Medpaces

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Medpaces

NasdaqGS:MEDP US58506Q1094
54
  • Value
    9
  • Growth
    93
  • Safety
    Safety
    1
  • Combined
    29
  • Sentiment
    41
  • 360° View
    360° View
    54
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) providing full-service clinical development services. The company operates in the biotechnology, pharmaceutical, and medical device industries, offering phase I-IV clinical development services, bio-analytical laboratory services, clinical human pharmacology, imaging, and electrocardiography reading support. Their operations are principally based in North America, Europe, and Asia. In the last fiscal year, the company had a market cap of $8988 million, profits of $656 million, revenue of $2109 million, and 5900 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 54 (better than 54% compared with alternatives), overall professional sentiment and financial characteristics for the stock Medpaces are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Medpaces. The consolidated Growth Rank has a good rank of 93, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 93% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 1 means that the share price of Medpaces is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 99% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 9, which means that the company has a riskier financing structure than 91% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 41, indicating professional investors are more pessimistic about the stock than for 59% of alternative investment opportunities. ...read more

more
Index
Employee Health US
NASDAQ
S&P MIDCAP
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
1 9 8 35
Growth
93 73 97 91
Safety
Safety
9 9 69 77
Sentiment
41 33 100 75
360° View
360° View
54 54 90 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
1 34 83 16
Opinions Change
50 22 50 50
Pro Holdings
n/a 56 92 92
Market Pulse
76 46 91 78
Sentiment
41 33 100 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
1 9 8 35
Growth
93 73 97 91
Safety Safety
9 9 69 77
Combined
29 29 65 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
18 42 30 37
Price vs. Earnings (P/E)
24 32 38 67
Price vs. Book (P/B)
3 17 3 33
Dividend Yield
1 1 1 1
Value
1 9 8 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
67 67 82 75
Profit Growth
47 33 73 51
Capital Growth
84 78 89 75
Stock Returns
89 59 87 75
Growth
93 73 97 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 62 100
Refinancing
3 8 3 13
Liquidity
1 1 100 90
Safety Safety
9 9 69 77

Similar Stocks

Discover high‑ranked alternatives to Medpaces and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.